- Home
- KOD vs AVXL Comparison
KOD vs AVXL Comparison
Compare KOD & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- AVXL
- Stock Information
- Founded
- KOD 2009
- AVXL 2004
- Country
- KOD United States
- AVXL United States
- Employees
- KOD N/A
- AVXL N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KOD Health Care
- AVXL Health Care
- Exchange
- KOD Nasdaq
- AVXL Nasdaq
- Market Cap
- KOD 795.5M
- AVXL 684.6M
- IPO Year
- KOD 2018
- AVXL N/A
- Fundamental
- Price
- KOD $16.43
- AVXL $7.49
- Analyst Decision
- KOD Buy
- AVXL Strong Buy
- Analyst Count
- KOD 7
- AVXL 3
- Target Price
- KOD $19.29
- AVXL $44.00
- AVG Volume (30 Days)
- KOD 964.2K
- AVXL 1.3M
- Earning Date
- KOD 11-13-2025
- AVXL 12-22-2025
- Dividend Yield
- KOD N/A
- AVXL N/A
- EPS Growth
- KOD N/A
- AVXL N/A
- EPS
- KOD N/A
- AVXL N/A
- Revenue
- KOD N/A
- AVXL N/A
- Revenue This Year
- KOD N/A
- AVXL N/A
- Revenue Next Year
- KOD N/A
- AVXL N/A
- P/E Ratio
- KOD N/A
- AVXL N/A
- Revenue Growth
- KOD N/A
- AVXL N/A
- 52 Week Low
- KOD $1.92
- AVXL $7.16
- 52 Week High
- KOD $21.17
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- KOD 48.57
- AVXL 30.16
- Support Level
- KOD $17.04
- AVXL $7.88
- Resistance Level
- KOD $19.26
- AVXL $7.59
- Average True Range (ATR)
- KOD 1.79
- AVXL 0.40
- MACD
- KOD -0.40
- AVXL -0.12
- Stochastic Oscillator
- KOD 5.00
- AVXL 14.02
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.